We increase production of COVID-19 drugs
Since the beginning of the pandemic we have delivered 79,4 million units in 43 products, where the greatest increase is reflected in anesthetics and sedatives with a 153% growth versus the previous year, followed by corticosteroids with a 38% and antibiotics with a 6%; medications that have been vital to the care of patients affected by COVID-19.
This is our commitment to the health of all.